The majority of men diagnosed with prostate cancer have high 10-year survival rates due to improved screening, detection, and treatments ([@bibr35-1557988318784395]). Unfortunately, these men have heightened risk for depression related to unmet psychosocial needs, prostate cancer--related symptoms, and treatment side effects that can include sexual dysfunction and urinary incontinence ([@bibr3-1557988318784395]). Many men with prostate cancer can suffer from additional health problems (i.e., sexual dysfunction and heart disease) that may contribute to depressive symptoms ([@bibr9-1557988318784395]; [@bibr25-1557988318784395]). Depression among men with prostate cancer has emerged as a significant issue with prevalence reported at 16% to 30% ([@bibr5-1557988318784395]; [@bibr26-1557988318784395]; [@bibr27-1557988318784395], [@bibr28-1557988318784395]; [@bibr33-1557988318784395]). Depression in prostate cancer is associated with men experiencing a loss of masculine identity ([@bibr30-1557988318784395]). Severe depression is a known risk for suicide, especially among older prostate cancer patients ([@bibr14-1557988318784395]). Although awareness of depression in prostate cancer has grown, the wider men's health literature suggests depression among men is underdiagnosed ([@bibr17-1557988318784395]). Research attention has thus been increasingly devoted to the specificities of men's depressive symptoms, the contexts in which they are experienced, and the methods and tools used to formally evaluate depression in men.

The generic diagnostic criteria for major depressive disorder, as per the Diagnostic and Statistical Manual (DSM-5), have been critiqued as gender neutral and insufficient to comprehensively evaluate depression in men ([@bibr29-1557988318784395]). At a broad level, such critiques have produced a focus on highlighting male-specific depressive symptoms and the design and testing of tools to more accurately diagnose and treat men's depression. Systematic reviews and population studies support these efforts by arguing for the existence of a subtype of depression in men characterized by alcohol/substance use and externalizing symptoms including anger and irritability ([@bibr2-1557988318784395]; [@bibr15-1557988318784395]). Expansion of the assessment of depression may be particularly important for men with prostate cancer. For example, [@bibr26-1557988318784395] argued that psychological evaluation of men with prostate cancer should be informed by better understanding their cancer-related symptoms, rather than focusing on the major depressive disorder criteria. This was based on findings that men who experience prostate cancer--related urinary incontinence and those treated with androgen deprivation therapy, who in turn experienced fatigue and insomnia, were more likely to be depressed ([@bibr26-1557988318784395]). Unpleasant emotions and social withdrawal from others were also highlighted as significant factors associated with depression severity in a sample of 800 prostate cancer patients ([@bibr27-1557988318784395]).

Nonetheless, depression scales that emphasize internalizing symptoms in the diagnosis of major depressive disorder continue to be used widely in prostate cancer patients. For example, the Patient Health Questionnaire-9 (PHQ-9) performed reliably in testing several aspects of depression in cancer patients ([@bibr11-1557988318784395]); however, according to Sharpley et al. ([@bibr29-1557988318784395]), the PHQ-9 does not fully capture the dimensions of depression as they manifest in men with prostate cancer. Specifically, the PHQ-9 and the Gotland Male Depression Scale (GMDS) were compared for their capacity to measure the prevalence of depression in 191 men with prostate cancer, and approximately 24% of the men screened as depressed on the GMDS were not identified by the PHQ-9 ([@bibr29-1557988318784395]). The GMDS has, however, drawn criticisms regarding psychometric validity, highlighting the need for measurement refinement amid the emergence of other male depression scales ([@bibr20-1557988318784395]). Among the newer scales, the Male Depression Risk Scale-22 (MDRS-22) has shown much promise and has been validated in general populations of Canadian and Australian men to identify males at risk of depression ([@bibr23-1557988318784395]; [@bibr24-1557988318784395]). The scale assesses six broad externalizing domains of depression symptoms in men, including emotion suppression and anger and aggression, and may offer improved detection and early intervention among males at risk for depression and suicidal ideation.

The objective of the current study was to evaluate and compare PHQ-9 and MDRS-22 self-report data among men with prostate cancer relative to those with and without comorbidities (e.g., cardiovascular problems, arthritis, and chronic pain). The second aim was to evaluate the predictive ability of the MDRS-22 in identifying recent suicidal ideation in this population. Given evidence suggesting that men with prostate cancer who experience comorbidity report greater psychosocial stress and poorer outcomes ([@bibr9-1557988318784395]; [@bibr25-1557988318784395]), it was predicted that higher scores for prototypic and male-specific depression symptoms would be observed among men reporting comorbidity.

Methods {#section1-1557988318784395}
=======

Participants {#section2-1557988318784395}
------------

This study used a convenience sample of 100 Canadian men with prostate cancer, recruited online and via social media. Men self-identified as having prostate cancer and indicating year of diagnosis and providing information regarding current treatment and symptoms.

Measures {#section3-1557988318784395}
--------

Demographic information included country and province of residence, age, employment status, education level, sexual identity, cultural affiliation, year diagnosed with prostate cancer and year treated, prostate cancer treatment\[s\], and current treatment. Data for comorbidity were collected using an item labeled "Other health challenges" to which respondents could indicate "yes" \[Please specify\] or "no." The PHQ-9 ([@bibr13-1557988318784395]), developed from the diagnostic criteria for major depressive disorder, comprises nine items reflecting the diagnostic criteria in the DSM-V ([@bibr1-1557988318784395]). Respondents indicated how often (0 = "not at all," 1 = "several days," 2 = "more than half the days," and 3 = "nearly every day") they had been bothered by any of the listed problems over the last 2 weeks (see [Table 1](#table1-1557988318784395){ref-type="table"} for items). The PHQ-9 has excellent validity for individuals with mild, moderate, and severe depression ([@bibr13-1557988318784395]), with aggregate scores ranging from 0 to 27 that map minimal depression (0--4), mild depression (5--9), moderate depression (10--14), moderately severe depression (15--19), and severe depression (20--27). The MDRS-22 comprises 22 items and six subscales focused on externalizing depression symptoms ([@bibr21-1557988318784395]). Respondents, thinking back over the last month, responded to each item considering how often (0 = *not at all* to 7 = *almost always*) specific statements applied to them (see [Table 2](#table2-1557988318784395){ref-type="table"} for MDRS-22 subscales). The MDRS-22 exhibits test--retest stability and excellent psychometric properties ([@bibr19-1557988318784395]) and has been validated in Australian and Canadian samples with the total score characterizing those in the low (0--31), elevated (32--50), high (51--86), and extreme ranges (87--154; [@bibr23-1557988318784395]).

###### 

Group Comparison for PHQ-9 Items.

![](10.1177_1557988318784395-table1)

                                                                                                                                                                           Total sample, *N* = 100   No comorbidity, *n* = 62   Comorbidity, *n* = 38   Group comparison                
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------ ------------------------- -------------------------- ----------------------- ------------------ ------------ ------
  Little interest or pleasure in doing things                                                                                                                              0.72 (0.95)               0.60 (0.91)                0.92 (1.00)             2.48               .099         0.33
  Feeling down, depressed, or hopeless                                                                                                                                     0.68 (0.82)               0.52 (0.74)                0.94 (0.87)             7.00               .010         0.52
  Trouble falling asleep or sleeping too much                                                                                                                              1.00 (1.03)               0.79 (0.91)                1.34 (1.15)             7.11               .009         0.53
  Feeling tired or having little energy                                                                                                                                    1.14 (1.09)               0.81 (0.97)                1.68 (1.07)             17.81              **\<.001**   0.85
  Poor appetite or overeating                                                                                                                                              0.62 (0.87)               0.50 (0.82)                0.82 (0.92)             3.15               .079         0.36
  Feeling bad about yourself or that you are a failure or have let yourself or family down                                                                                 0.56 (0.70)               0.47 (0.67)                0.71 (0.73)             2.88               .093         0.34
  Trouble concentrating on things, such as reading the newspaper or watching television                                                                                    0.63 (0.87)               0.48 (.80)                 0.86 (0.93)             4.75               .032         0.34
  Moving or speaking so slowly that other people could have noticed. Or the opposite being so fidgety or restless that you have been moving around a lot more than usual   0.30 (0.58)               0.19 (.44)                 0.47 (0.72)             5.81               .018         0.47
  Thoughts that you would be better off dead or of hurting yourself in some way                                                                                            0.20 (0.55)               0.16 (.45)                 0.26 (0.55)             0.81               .372         0.20

*Note.* ^a^PHQ-9 item scores range 0--3. PHQ-9 = Patient Health Questionnaire-9; *SD* = standard deviation.

###### 

Group Comparison for MDRS-22 Subscales.

![](10.1177_1557988318784395-table2)

                         Total sample, *N* = 100   No comorbidity, *n* = 62   Comorbidity, *n*=38   Group comparison          
  ---------------------- ------------------------- -------------------------- --------------------- ------------------ ------ ------
  Emotion suppression    8.73 (7.73)               7.58 (6.96)                10.61 (8.61)          4.56               .035   0.38
  Drug use               1.03 (3.24)               0.50 (1.87)                1.89 (4.58)           4.77               .031   0.38
  Alcohol use            2.51 (4.97)               2.71 (5.35)                2.18 (4.32)           0.20               .656   0.11
  Anger and aggression   3.53 (5.18)               2.91 (4.37)                4.53 (6.22)           2.71               .103   0.30
  Somatic symptoms       5.14 (5.35)               4.56 (5.38)                6.08 (5.25)           1.22               .140   0.28
  Risk-taking            1.30 (2.61)               1.37 (2.44)                1.18 (2.88)           0.04               .843   0.07

*Note.* ^a^MDRS-22 subscales range 0--28 for emotion suppression, alcohol use, anger and aggression, and somatic symptoms; MDRS-22 subscales range 0--21 for the drug use and risk-taking subscales. MDRS = Male Depression Risk Scale-22; *SD* = standard deviation.

Procedure {#section4-1557988318784395}
---------

Following approval from the behavioral ethics review board at (University of British Columbia), the survey was embedded in an online prostate cancer psychosocial resource. The website and survey were launched in January 2017, highlighting the issue of depression in men with prostate cancer, and the opportunity for respondents to be entered into a \$500 cash prize draw by completing the survey. The survey was available for 3 months to April 2017, and recruitment was aided by targeted Facebook ads and social media posts inviting men with prostate cancer to respond by clicking on the hyperlinked survey. The survey landing page provided details about the study including consent, confidentiality regards respondent's demographic data, and its separate password protected storage from their survey responses, along with details about the aggregated data being shared as study findings in an academic publication and presentations. On completion of the survey, respondents were provided the URL of a men's depression website (<https://headsupguys.org/>), which provided visitors with male-specific depression information and supports.

Data Analysis {#section5-1557988318784395}
-------------

Analyses were undertaken in SPSS 22.0 (IBM Corp.). Descriptive statistics were used to characterize the sample based on self-reported sexuality, cultural affiliation, and highest education. Independent sample *t* tests were used to compare groups (i.e., those with and without self-reported comorbidity) on age, and χ^2^ analyses were used to evaluate the associations between treatment groups (i.e., current active treatment and watchful waiting), recent diagnosis (i.e., last 12 months), and highest education level. Reliability for the PHQ-9 and MDRS-22 subscales was calculated using Cronbach's α coefficients. Multivariate analysis of covariance was conducted on the PHQ-9 items and MDRS-22 subscales, controlling for current treatment and age. χ^2^ analysis evaluated established PHQ-9 categories (i.e., normal PHQ-9 = 0--4, minimal PHQ-9 = 5--9, mild PHQ-9 = 10--14, and moderate--severe PHQ-9 = 15--27) according to those with and without comorbidities. Hierarchical logistic regression was undertaken to predict recent (past 2 weeks) suicide ideation, as assessed by PHQ-9 item nine, controlling for age, recent diagnosis, current treatment, and sexuality (step 1) and comorbidity (step 2), with MDRS-22 subscales entered at step 3.

Results {#section6-1557988318784395}
=======

Sample Characteristics {#section7-1557988318784395}
----------------------

Mean age of the sample was 64.8 (standard deviation \[*SD*\] = 7.18) years, ranging 47 to 85. The vast majority of the sample identified as heterosexual (*n*=96), and four participants identified as gay, bisexual, or preferred not to say. Most (*n* = 87) participants identified as Caucasian. More than 60% of the sample reported higher education: some college/trade school (*n* = 19); graduation from college/trade school (*n* = 23); some university (*n* = 7); undergraduate degree (*n* = 17); and graduate degree (*n* = 21). Of the 38 participants indicating a comorbidity in addition to their prostate cancer diagnosis, only one reported a diagnosis of depression. A total of 11 participants reported multimorbidities. The remaining cases reported challenges with cardiovascular health (*n* = 10), arthritis (*n* = 7), chronic pain (*n* = 2), or other (*n* = 8; gallstones, diabetes). Recent suicidal ideation was relatively infrequent in the present sample (*n* = 14). One-third (*n* = 33) of the sample were receiving active treatment, and just over half (*n*=54) reported a prostatectomy.

There was no significant age difference between those without comorbidity (*M* = 64.55 years, *SD* = 7.07) and those reporting comorbidity (*M* = 65.24 years, *SD* = 7.42), *p* = .644. There was no association between those reporting comorbidity and current active treatment (*n* = 33, χ^2^(1) = 0.40, *p* = .522), watchful waiting (*n* = 22, χ^2^(1) = 1.72, *p* = .189), recent diagnosis of prostate cancer (i.e., last 12 months; *n* = 35, χ^2^(1) = 0.16, *p* = .690), highest education level (χ^2^(6) = 8.56, *p* = .200), or recent suicidal ideation (*n* = 6, χ^2^(1) = 0.16, *p* = .686).

Scale Reliability {#section8-1557988318784395}
-----------------

The PHQ-9 demonstrated satisfactory internal consistency (Cronbach's α = .89). For the MDRS-22, all subscales reported satisfactory internal consistency: emotion suppression (α =.88), drug use (α =.91), alcohol use (α =.91), anger and aggression (α =.92), somatic symptoms (α =.67), though internal consistency was low for the risk-taking subscale (α =.59). A subsequent sensitivity analysis of the risk-taking subscale, however, identified that the risk-taking subscale was internally consistent for those \<65 years (*n* = 46, α =.70) relative to males ≥65 years (*n* = 54, α =.07).

Comparison of Symptom Profiles {#section9-1557988318784395}
------------------------------

For the PHQ-9 total score, those with comorbidity reported significantly higher depression scores (*M* = 8.02, *SD* = 5.56) compared to those without comorbidity (*M* = 4.52, *SD* = 5.19), *F*(1, 96) = 10.87, *p* = .001, Cohen's *d* = 0.65. Neither current treatment (*p* = .738) or age (*p* = .097) was significant covariates. When the nine PHQ-9 symptoms were examined in a multivariate analysis, a significant omnibus effect was observed, Λ = 0.811, *F*(9, 90) = 2.33, *p* = .021, partial η^2^ = .189. Current treatment (*p* = .832) and age (*p* = .789) were not significant covariates. Significant univariate effects were observed for five major depression symptoms; higher scores were observed for those with comorbidity for low mood, sleep disturbance, fatigue, concentration difficulty, and psychomotor disturbance (see [Table 1](#table1-1557988318784395){ref-type="table"}).

Categorical analysis was undertaken according to PHQ-9 depression categories. A significant association indicated that those with comorbidity were less likely to be in the normal range and more likely to be in the mild and moderate symptom ranges than those with no comorbidity χ^2^(3, *N* = 100) = 8.024, *p* = .046. The same association held for the MDRS-22 χ^2^(3, *N* = 100) = 8.30, *p* = .040 (see [Figure 1](#fig1-1557988318784395){ref-type="fig"}).

![PHQ-9 and MDRS-22 categories (percentage with comorbidity).](10.1177_1557988318784395-fig1){#fig1-1557988318784395}

For the MDRS-22 total score, there was a nonsignificant trend for those with comorbidity to report higher scores (*M* = 26.47, *SD* = 21.24) compared to those without comorbidity (*M* = 19.65, *SD* = 17.64), *F*(1, 96) = 3.92, *p* = .051, Cohen's *d* = 0.35, with neither current treatment (*p* = .931) or age (*p* = .097) significant as covariates. When the MDRS-22 subscales were examined in a multivariate analysis, a significant multivariate effect was observed, Λ=.863, *F*(6, 91) = 2.41, *p* = .033, partial η^2^ = .132, with neither current treatment (*p* = .992) or age (*p* = .058) significant covariates. At the univariate level, there was a significant effect for the emotion suppression subscale, *F*(1, 96) = 4.56, *p* = .035, and the drug use subscale, *F*(1, 96) = 4.77, *p* = .031. In both instances, scores were higher among men with comorbidities.

Suicidal Ideation {#section10-1557988318784395}
-----------------

Of the 14 respondents who endorsed suicidal ideation, the PHQ-9 cut-off score for "moderate depression" identified 71.4% (*n* = 10) of those men, while the MDRS-22 "elevated" cut-off identified 85.7% (*n* = 12). Bivariate correlations were calculated between PHQ-9 total scores and the MDRS-22 subscales. Significant correlations were observed for five of the MDRS-22 subscales; emotion suppression (*r* = .66, *p* \< .001), drug use (*r* = .22, *p* = .025), anger and aggression (*r* = .59, *p* \< .001), somatic symptoms (*r* = .46, *p* \< .001), and risk-taking (*r*=.41, *p* \< .001). The logistic regression model was not significant with the control variables entered at either step 1 (χ^2^(4) = 3.51, *p* =.447) or step 2 (χ^2^(5) = 3.77, *p* = .609) but was significant when the six MDRS-22 subscales were simultaneously entered at step 3 (χ^2^(11) = 33.75, *p* \< .001). The model explained 51.8% of variance in recent suicide ideation, with the MDRS-22 subscales accounting for 45.1% of variance (Nagelkerke *R*^2^). Increasing MDRS-22 emotion suppression subscale scores were a significant predictor (Wald = 5.78, odds ratio \[*OR*\] = 1.18, *p* = .016), with a trend observed for the anger and aggression subscale (Wald = 3.80, *OR* = 1.19, *p* = .051).

Discussion {#section11-1557988318784395}
==========

There was a consistent pattern of higher scores for major depression symptoms for those men with prostate cancer reporting comorbidities (i.e., cardiovascular disease and arthritis), with a robust moderate effect size for the group difference in PHQ-9 total scores. Those reporting comorbidities were more likely to be in the mild or moderate--severe range on the PHQ-9 than those without other health challenges. Specific effects were noted for low mood, sleep disturbance, fatigue, concentration difficulty, and psychomotor disturbance. This suggests that the likelihood of depression may increase in men experiencing prostate cancer who have comorbidities. These results indicate that it is not only the likelihood of depression severity that increases but also that the expression of depressive symptoms may be different for men with prostate cancer who also report comorbidity. Given that many men with prostate cancer are in their sixth, seventh, and eighth decades, this is an important consideration in routinely evaluating depression levels in men with prostate cancer. It is likely that many of these men were treated with polypharmacy agents, some of which in and of themselves might heighten their risk for depression ([@bibr10-1557988318784395]). There was no significant difference between those with and without comorbidities with regards to the suicidal ideation item on the PHQ-9. While this may reflect an equivalent degree of suicidal ideation between the two groups, there may also be benefit in more fully evaluating suicidality in men with prostate cancer beyond the single PHQ-9 item, "*Thoughts that you would be better off dead, or of hurting yourself in some way*."

Patterns for the MDRS-22 were less consistent. Those reporting additional health challenges had significantly higher scores for the emotion suppression and drug use subscales. The drug use effect might be explained by respondents with comorbidity being reliant on polypharmacy agents for a range of conditions. In this regard, the MDRS-22 likely yields diverse interpretations of the drug use items wherein some respondents may use illicit drugs recreationally, responding on that basis, while others such as the current sample might be responding based on their prescription drug use. Nonetheless, since men with comorbidity were markedly more distressed (based on PHQ-9 scores) than those without comorbidity, this difference remains cause for some concern---perhaps suggesting the overuse of drugs for emotional coping and/or for management of a higher pain burden. The effect for emotion suppression, which demonstrated the strongest correlation with the PHQ-9, suggests that those with comorbidity may attempt to self-censor and withhold the expression of negative emotion. Such responses may actually increase the likelihood of developing additional physical and mental health problems ([@bibr12-1557988318784395]; [@bibr16-1557988318784395]). Furthermore, the current study findings indicate that the MDRS-22 risk-taking subscale may be less reliable in older men (i.e., those ≥65 years). This may be somewhat expected and likely reflects older men's more conservative practices.

Beyond differences in symptom expression between men with and without comorbidities, unique associations were reported between overall depressive severity and two male-specific domains of the MDRS-22. Based on the regression analyses, anger and aggression also appeared to be salient among men with prostate cancer and comorbidity, while emotion suppression appeared to be an important factor associated with prototypic symptoms of depression in men with prostate cancer in general. As older men, respondents may have aligned to traditional masculine ideals around stoicism and relied on anger and aggression to express their emotions, which in turn can manifest as maladaptive coping. Experiencing prostate cancer and comorbidity may further threaten one's sense of self as a man, evoking unmodulated anger (in protest and/or in compensation) for their compromised health. Results from the regression analyses indicated that the MDRS-22 subscales accounted for a large proportion of variance in the PHQ-9 scores, approximately 48% for those without comorbidity and 53% of variance for those with comorbidities. The current study findings suggest evaluation of emotion suppression in men with prostate cancer, along with anger and aggression in men with prostate cancer and comorbidity as important avenues of future research. That emotion suppression was identified to be a significant predictor of suicide ideation with a trend also observed for anger and aggression, suggests that additional research attention is paid to more fully apprehend and address these potential connections.

Clinical Implications {#section12-1557988318784395}
=====================

The current study findings have implications for researchers and care providers. Both groups should be aware of comorbidities in men with prostate cancer as depression risk factors, given this appears to be associated with higher PHQ-9 scores in the current sample. Supporting this recommendation, depression also appears to be underdiagnosed in this population. For example, among those reporting comorbidity, only one participant self-reported a diagnosis of depression. [Figure 1](#fig1-1557988318784395){ref-type="fig"} shows that there were 13 cases (i.e., 34%) in the comorbidity subgroup achieving the PHQ-9 cut-off score for either mild or moderate--severe depression. The observation that 22 of the 100 respondents' PHQ-9 scores also indicated mild to moderate--severe depression supports estimates of prevalence in the literature ([@bibr5-1557988318784395]; [@bibr26-1557988318784395]; [@bibr27-1557988318784395], [@bibr28-1557988318784395]; [@bibr33-1557988318784395]). Furthermore, given their association with PHQ-9 scores, emotion suppression and anger and aggression in men should be taken into account by clinicians working with men who experience prostate cancer. This finding supports work by [@bibr30-1557988318784395] and others ([@bibr17-1557988318784395]; [@bibr21-1557988318784395]) indicating that a range of male-specific symptoms exist beyond those identified by generic depression screening tools, and that nuanced differences in the expression of such symptoms may emerge in the context of prostate cancer and comorbid conditions.

A proportion of men with prostate cancer will also experience suicidal ideation. Emotion suppression was found to be predictive of suicidal ideation in the present sample. When assessing for depression in this population, sensitive clinical enquiry regarding suicidal thoughts is suggested, along with assessing the likelihood of emotion suppression, given the potential association between these two constructs. Taking a wider view, adopting brief general screening tools such as the Distress Thermometer, a single-item measure validated in populations of men experiencing prostate cancer ([@bibr4-1557988318784395]), may also assist as a way to introduce clinical conversations about suicidal thinking.

In terms of prevention and treatment of depressive symptoms, [@bibr32-1557988318784395] advocated for peer supports as an effective way to increase men's resilience for coping with prostate cancer and alleviating depressive symptoms. A systematic review of randomized controlled trials drawn from programs to improve the psychological well-being of men with prostate cancer highlighted 11 effective interventions ([@bibr3-1557988318784395]). These included online psychoeducation and moderated peer forums; however, these interventions and their evaluations were not based on translational knowledge about masculinity and male-specific symptoms of depression ([@bibr3-1557988318784395]). [@bibr7-1557988318784395] asserted the need to appeal to men's masculine values through group-based physical exercise interventions. Such approaches may to promote social connectedness and reduce depression among men with prostate cancer ([@bibr6-1557988318784395]; [@bibr8-1557988318784395]). Building on these insights and recommendations by [@bibr31-1557988318784395], future work might also focus on prevention and treatments of depression among specific subgroups, with formal evaluation of prostate cancer psychosocial programs inclusive of end-users' depressive symptoms and scores over time.

More broadly, findings have implications for the field of men's depression research. In the present sample, the MDRS-22 cut-off identified additional cases of suicidality that fell below the PHQ-9 cut-off. As suggested by others ([@bibr22-1557988318784395]), case identification may be improved by supplementing the use of standard depression symptom rating scales with male-specific measures. Furthermore, emotion suppression predicted suicidality in the present sample. This accords with recent population-based epidemiological work indicating that men's stoicism is a robust predictor of suicidal ideation ([@bibr18-1557988318784395]). Ongoing attention to men's use of emotion suppression and tendency for stoicism is indicated.

Study Limitations {#section13-1557988318784395}
=================

The current study has several limitations: the use of nonprobability sampling precludes generalizability of findings; the cross-sectional design prohibits causal inference; the exclusive use of self-report measures including the lack of follow-up screening and diagnosis by a clinician; and the small sample size. Furthermore, suicidal ideation was assessed by a single item from the PHQ-9; however, research has previously supported use of this item ([@bibr34-1557988318784395]). Future studies should use large samples and longitudinal designs to fully examine the role of age, comorbidities, and treatment modalities in men's depression across the prostate cancer trajectory.

Summary {#section14-1557988318784395}
=======

To address depression in men with prostate cancer, more effective screening for depressive symptoms is needed, and future interventions should be designed and formally evaluated on understandings of relative depression risk and specific symptomatology in men with prostate cancer. By highlighting the increased risk for depression in men with prostate cancer who have comorbidity, and the predictive nature of emotion suppression and anger and aggression on PHQ-9 scores, the current study reveals the need for asking additional clinical and research questions of this subgroup of men who are vulnerable to depression.
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